Form 4: Aprea Therapeutics CEO Oren Gilad Acquires Shares and Stock Options

Aprea Therapeutics' CEO, Oren Gilad, reports acquisition of common stock and stock options, signaling changes in his beneficial ownership.

Summary

• On March 28, 2024, Oren Gilad, the CEO of Aprea Therapeutics, acquired 6,725 shares of common stock as restricted stock units (RSUs) at $0.00.
• These RSUs will vest in three equal annual installments starting March 28, 2025, contingent upon continued employment.
• Gilad also acquired 26,900 stock options with an exercise price of $6.69, vesting 25% on March 28, 2025, and the remainder ratably over the following 36 months, also contingent upon continued employment.
• Following these transactions, Gilad directly owns 331,495 shares of common stock and 26,900 stock options.
• He also indirectly owns 1,200 shares through his daughter and 600 shares through his son, but disclaims beneficial ownership of these shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO acquiring shares and options suggests confidence, but it's a routine transaction.

Positives

• The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.
• The vesting schedule of the RSUs and stock options incentivizes the CEO to remain with the company for the long term.

Risks

• The vesting of the RSUs and stock options is contingent upon the CEO's continued employment, creating a potential risk if he were to leave the company.
• The value of the stock options is dependent on the company's stock price exceeding the exercise price of $6.69.

Future Outlook

The CEO's holdings will increase over time as the RSUs and stock options vest, assuming continued employment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's sentiment and potential future actions.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Vesting schedules are a common practice to incentivize long-term commitment.
• The specific terms of the options and RSUs (exercise price, vesting schedule) are typical for executive compensation packages in the biotechnology industry.

Stakeholder Impact

• Shareholders may view the CEO's increased stake in the company positively.
• Employees may see it as a sign of leadership's commitment.
• The impact on customers, suppliers, and creditors is likely minimal.

Next Steps

• The CEO will continue to vest in the RSUs and stock options over the next three years, contingent upon continued employment.
• The market will likely monitor future Form 4 filings for any further changes in the CEO's beneficial ownership.

Key Dates